
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc. reported a revenue of $79.6 million, reflecting a year-over-year increase of 6% and aligning closely with expectations, highlighting the firm's ongoing focus on scaling higher-margin, recurring technology revenue. The company is poised to add approximately 40 net new platform clients in FY25, significantly up from 21 in the previous year, driven by successful cross-selling strategies to an extensive base of over 900 application clients. Additionally, Health Catalyst has modestly revised its EBITDA guidance upward by $2 million, suggesting confidence in achieving operational efficiencies and a favorable market position as it anticipates strong business signings in the upcoming quarters.
Bears say
Health Catalyst Inc. is facing significant challenges that contribute to a negative outlook for its stock. The company’s EBITDA guidance of approximately $4 million for 2025, which is down 55% from consensus expectations of $8.8 million, indicates a concerning inability to meet performance targets amid a slower-than-anticipated ramp-up in the second half of 2025. Additionally, revenue guidance of $79 million for the first quarter of 2025 falls short of analysts' expectations of $82 million, along with complications arising from shifts in business mix and ongoing challenges related to the adoption of new technology platforms.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares